By specifically blocking the GnRH receptor, a GPCRs targeted drug, Degarelix, a FDA approved drug, is applied to treat advanced prostate cancer by decreasing the amount of testosterone [63]. The gene discussed is GNRHR; the disease is prostate carcinoma.